1. Home
  2. KREF vs ENTA Comparison

KREF vs ENTA Comparison

Compare KREF & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KKR Real Estate Finance Trust Inc.

KREF

KKR Real Estate Finance Trust Inc.

HOLD

Current Price

$7.22

Market Cap

458.9M

Sector

Real Estate

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$14.21

Market Cap

486.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KREF
ENTA
Founded
2014
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
458.9M
486.3M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
KREF
ENTA
Price
$7.22
$14.21
Analyst Decision
Buy
Strong Buy
Analyst Count
7
5
Target Price
$10.33
$20.40
AVG Volume (30 Days)
988.7K
219.3K
Earning Date
02-03-2026
02-09-2026
Dividend Yield
14.01%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,844,000.00
$66,980,000.00
Revenue This Year
$571.48
$0.99
Revenue Next Year
$9.54
$0.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.58
52 Week Low
$7.11
$4.09
52 Week High
$11.53
$17.15

Technical Indicators

Market Signals
Indicator
KREF
ENTA
Relative Strength Index (RSI) 31.09 58.57
Support Level $7.22 $13.18
Resistance Level $8.40 $15.55
Average True Range (ATR) 0.25 0.66
MACD -0.11 0.18
Stochastic Oscillator 11.01 59.44

Price Performance

Historical Comparison
KREF
ENTA

About KREF KKR Real Estate Finance Trust Inc.

KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: